Hello, I have some questions and concerns about the mRNA vaccines that I'd like to share and ask.

There seems to be a large difference between the natural route of infection with Covid and the route of the spike protein with mRNA vaccination. With a natural infection with Covid, the virus binds to the ACE-2 protein, and enters the cell in that way. In many cases it remains confined to the pneumocytes. In a minority of the cases the virus further enters the body, and even then the virus gets presented to the immune system via the MHC complexes. But the vaccine gets introduced to the body via a a LNP particle and injected into the muscle. It doesn't have its own receptor, and it can aspecifically enter any cell. There are very few (and limited) studies performed with regards to the biodistribution of the vaccine, and even then they were only performed on mice and monkeys. What is known is that it enters muscle cells and antigen presenting cells. In other words, this protein would otherwise never be presented to the immune system in this way, because the spike protein itself gets expressed on the cell membrane of these cells, and does not get presented via MHC complexes like it would with a natural Covid infection. We do not know if this can be harmful or not. And it is also not clear what could happen if the vaccine enters endothelial cells, neurons, or other cells or tissues. Isn't it possible that the myocarditis cases being seen now, are a result of the vaccine entering cardiac muscle cells and expressing the spike protein on these cells? The vaccine mRNA is also created in such a way as to optimalize the production of the spike protein. This was done by modifying the Cap and by elongating the poly-A tail. The codons were also chosen so that this mRNA is more strongly transcribed than the cell's own mRNA. the mRNA does not enter the cells' cytosol in the normal way, but in an aspecific way. Does this have consequences for the cells, which would normally never produce the spike protein? Isn't it wise to apply caution in vaccinating a young, healthy population due to the above (<45 years)?